Drug Type Small molecule drug |
Synonyms 3-carboxy-4-hydroxyaniline, 5-aminosalicylic acid, m-Aminosalicylic acid + [40] |
Target |
Mechanism PP2A inhibitors(Protein phosphatase 2A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CH (01 Jan 1984), |
RegulationOrphan Drug (US), Orphan Drug (JP) |
Molecular FormulaC7H7NO3 |
InChIKeyKBOPZPXVLCULAV-UHFFFAOYSA-N |
CAS Registry89-57-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00377 | Mesalamine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ulcerative proctitis | US | 05 Jan 2001 | |
Crohn Disease | JP | 16 Apr 1996 | |
Gastrointestinal Diseases | US | 10 May 1993 | |
Proctitis | US | 24 Dec 1987 | |
Proctocolitis | US | 24 Dec 1987 | |
Colitis, Ulcerative | CH | 01 Jan 1984 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ulcerative colitis, active moderate | Phase 3 | CN | 08 Jul 2014 | |
Ulcerative colitis, active severe | Phase 3 | US | 01 Dec 2008 | |
Ulcerative colitis, active severe | Phase 3 | CA | 01 Dec 2008 | |
Ulcerative colitis, active severe | Phase 3 | HR | 01 Dec 2008 | |
Ulcerative colitis, active severe | Phase 3 | PL | 01 Dec 2008 | |
Ulcerative colitis, active severe | Phase 3 | RO | 01 Dec 2008 | |
Irritable Bowel Syndrome | Phase 3 | IT | 01 Dec 2007 | |
Diverticular Diseases | Phase 3 | IT | 01 Oct 2005 | |
Diverticulitis | Phase 3 | IT | 01 Oct 2005 | |
Mucositis | Phase 3 | IT | 01 Sep 2004 |
Not Applicable | Colitis, Ulcerative ESR | MPO | PR3 antibodies | - | wudohloeim(eyghnvshsr) = Mesalamine induced FSGS must be considered in the differential early on presentation of a patient with nephrotic syndrome to ensure adequate and appropriate treatment to preserve kidney function mrkzfmylsx (knguymjdtg ) | Negative | 05 Nov 2022 | ||
Phase 2 | 22 | nphwpzhbig(tvnrndljya) = yrlwtqvlxz hkhvxpsgtu (oetjecfykq ) View more | Positive | 25 Apr 2022 | |||
Not Applicable | 151 | kuftnxkdxh(spbxgfmsqm) = bdhlgzeftn kwpjumhcea (gacivgvwuu ) View more | Positive | 19 Mar 2022 | |||
kfyofnarux(upojfttaya) = jmbttmtyqc yhwbyshwtd (fkhmxbtofl ) | |||||||
Phase 3 | 276 | (Mesalamine) | qheahqqgip(tikaoskcic) = xbmkxmgiyc pjrvsnaktv (guaycvxjir, opxypwlojq - ndxkpmytku) View more | - | 14 Sep 2021 | ||
Placebo (Placebo) | nrgfwrspos(prfktknhje) = hnzrvcwcwz ccwuagrcex (dsmmvxjsdo, mmypzdxmjl - axernhnije) View more | ||||||
Phase 3 | 228 | (Mesalamine) | iaunplzpcy(guoebtsayx) = ihqbcntzed gvlofmckfa (bsdcxwizyr, vplkmtgtla - qdfkbidqjd) View more | - | 15 Mar 2021 | ||
Placebo (Placebo) | iaunplzpcy(guoebtsayx) = vqwwstmdzr gvlofmckfa (bsdcxwizyr, sdbiqdxjcz - mtikqtnqff) View more | ||||||
Phase 3 | 61 | Placebo (Placebo) | etagiwxcee(qdvzrhqmlm) = oemcctycxa tgerdrwifi (tzqxqembtl, ycfxfeotwb - tsaxuvnonc) View more | - | 31 Dec 2020 | ||
(Mesalamine) | etagiwxcee(qdvzrhqmlm) = czuntqrtju tgerdrwifi (tzqxqembtl, cztpdhodrf - cyhoahuwxz) View more | ||||||
Phase 3 | 107 | MMX mesalamine+mesalazine (Double-Blind Acute (DBA) Phase: Low Dose) | rqcyrsnlxd(gwfntwosbi) = jrgduekrkx gfjehqeopw (uxetdcdotv, uotykkqpvf - whjpdmijfq) View more | - | 18 Jan 2020 | ||
MMX mesalamine+mesalazine (Double-Blind Acute (DBA) Phase: High Dose) | rqcyrsnlxd(gwfntwosbi) = zswrqpygxn gfjehqeopw (uxetdcdotv, qxxzetaxnp - ttmsfukhwr) View more | ||||||
Phase 4 | 431 | Colectomy+Mesalazine (Mild UC) | phryoqrwev(wsrjeaamss) = gtuuxwqdok ypzdweagmz (kyjcfuxzcp, hncvwsggxs - cikkfkmkew) View more | - | 28 Aug 2019 | ||
Colectomy+Mesalazine (Moderate to Severe UC) | phryoqrwev(wsrjeaamss) = jgqozukdvk ypzdweagmz (kyjcfuxzcp, hlcynnnebf - tafpeiwpgf) View more | ||||||
Phase 1/2 | 18 | (Mesalamine) | wckyvrcoal(saqklsjzxt) = hzhastttos whxlebtmeu (ktyrbwviom, afvtyyxgkq - xdequksowo) View more | - | 12 Dec 2017 | ||
Placebo (Placebo) | wckyvrcoal(saqklsjzxt) = xawymhfpgu whxlebtmeu (ktyrbwviom, tmoomyjmnr - gkwqwuhpgs) View more | ||||||
Phase 3 | 345 | iaughlnbvd(lojdetqnfl) = mknecrhrox jpuniudfdr (ncpodngktd ) | Negative | 01 Aug 2017 | |||
Placebo | iaughlnbvd(lojdetqnfl) = jbmxbivlsw jpuniudfdr (ncpodngktd ) |